Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-Line Afatinib 30 mg Versus 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in Taiwan.

Anticancer research - 1 Feb 2026

Hung Hui-Yang, Lee Tai-Huang, Chuang Cheng-Hao, Lee Mei-Hsuan, Wu Kuan-Li, Kuo Chia-Yu, Huang Hung-Ling, Huang Chung-Wen, Tsai Yu-Chen, Hung Jen-Yu, Chong Inn-Wen, Yang Chih-Jen

Abstract excerpt

BACKGROUND/AIM: Afatinib is an irreversible EGFR-TKI effective against uncommon EGFR mutations in non-small cell lung cancer (NSCLC), but the influence of mutation subtype and starting dose on treatment outcomes remains unclear. This study aimed to evaluate the clinical outcomes of patients with uncommon EGFR-mutated NSCLC treated with afatinib, focusing on whether a reduced starting dose (30 mg) provides...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Share to Taiwan

Source

Identifiers

PMID: 41617459
DOI: 10.21873/anticanres.17999

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-Line Afatinib 30 mg Versus 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in Taiwan.PMID 41617459Read ↗

Real-world Outcomes of First-line Afatinib in Patients with Non-small Cell Lung Cancer and Uncommon EGFR Mutations in South KoreaSemantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.Semantic proximity Read ↗

First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.Semantic proximity Read ↗

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.Semantic proximity Read ↗

Outcomes of Afatinib in Non-small Cell Lung Cancer Patients Harboring Uncommon Epidermal Growth Factor Receptor MutationsSemantic proximity Read ↗

Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.Semantic proximity Read ↗

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief ReportSemantic proximity Read ↗

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.Semantic proximity Read ↗

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.Semantic proximity Read ↗

Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice.Semantic proximity Read ↗

Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam.Semantic proximity Read ↗

Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.